Latest news

Thumbnail image for Lynparza granted Priority Review in US

Lynparza granted Priority Review in US

The first-in-class PARP inhibitor was also recently approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer.

13th January 2020

Previous  --   5 6 7 8 9 10 11 12 13 14   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download